141 related articles for article (PubMed ID: 19242368)
1. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
Akhtari M; Waller EK; Jaye DL; Lawson DH; Ibrahim R; Papadopoulos NE; Arellano ML
J Immunother; 2009 Apr; 32(3):322-4. PubMed ID: 19242368
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma.
du Rusquec P; Saint-Jean M; Brocard A; Peuvrel L; Khammari A; Quéreux G; Dréno B
J Immunother; 2014; 37(6):348-50. PubMed ID: 24911795
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
4. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
Bakacs T; Mehrishi JN; Moss RW
Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
[TBL] [Abstract][Full Text] [Related]
6. [Orbital myositis associated with ipilimumab].
Lecouflet M; Verschoore M; Giard C; Gohier P; Le Corre Y; Milea D; Martin L
Ann Dermatol Venereol; 2013; 140(6-7):448-51. PubMed ID: 23773743
[TBL] [Abstract][Full Text] [Related]
7. Delayed dermatologic hypersensitivity reaction secondary to ipilimumab.
Ludlow SP; Kay N
J Immunother; 2015 May; 38(4):165-6. PubMed ID: 25839442
[TBL] [Abstract][Full Text] [Related]
8. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
Kaehler KC; Egberts F; Lorigan P; Hauschild A
Melanoma Res; 2009 Oct; 19(5):333-4. PubMed ID: 19512947
[TBL] [Abstract][Full Text] [Related]
9. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma.
Ahmad S; Lewis M; Corrie P; Iddawela M
J Oncol Pharm Pract; 2012 Jun; 18(2):287-92. PubMed ID: 21807763
[TBL] [Abstract][Full Text] [Related]
11. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
Minor DR; Chin K; Kashani-Sabet M
Cancer Biother Radiopharm; 2009 Jun; 24(3):321-5. PubMed ID: 19538054
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
Bhatia S; Huber BR; Upton MP; Thompson JA
J Immunother; 2009; 32(2):203-5. PubMed ID: 19238020
[TBL] [Abstract][Full Text] [Related]
13. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
Weber J
Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
[TBL] [Abstract][Full Text] [Related]
14. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
15. Treating cancer by targeting the immune system.
Hwu P
N Engl J Med; 2010 Aug; 363(8):779-81. PubMed ID: 20818880
[No Abstract] [Full Text] [Related]
16. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
Hodi FS; Butler M; Oble DA; Seiden MV; Haluska FG; Kruse A; Macrae S; Nelson M; Canning C; Lowy I; Korman A; Lautz D; Russell S; Jaklitsch MT; Ramaiya N; Chen TC; Neuberg D; Allison JP; Mihm MC; Dranoff G
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3005-10. PubMed ID: 18287062
[TBL] [Abstract][Full Text] [Related]
17. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.
Barjaktarevic IZ; Qadir N; Suri A; Santamauro JT; Stover D
Chest; 2013 Mar; 143(3):858-861. PubMed ID: 23460165
[TBL] [Abstract][Full Text] [Related]
18. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
19. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
Gordon IO; Wade T; Chin K; Dickstein J; Gajewski TF
Cancer Immunol Immunother; 2009 Aug; 58(8):1351-3. PubMed ID: 19052742
[No Abstract] [Full Text] [Related]
20. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Weber J
Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]